Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening

BACKGROUND: To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Ejegod, Ditte Møller, Lagheden, Camilla, Bhatia, Ramya, Pedersen, Helle, Boada, Elia Alcañiz, Sundström, Karin, Cortés, Javier, Josë, F. Xavier Bosch, Cuschieri, Kate, Dillner, Joakim, Bonde, Jesper
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7203972/
https://ncbi.nlm.nih.gov/pubmed/32375689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06888-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires